These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26099891)

  • 21. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals.
    Peirano G; Costello M; Pitout JD
    Int J Antimicrob Agents; 2010 Jul; 36(1):19-23. PubMed ID: 20359869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-spectrum beta-lactamase-producing Escherichia coli infections in children: are community-acquired strains different from nosocomial strains?
    Morgand M; Vimont S; Bleibtreu A; Boyd A; Thien HV; Zahar JR; Denamur E; Arlet G
    Int J Med Microbiol; 2014 Nov; 304(8):970-6. PubMed ID: 25023074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors and clinical outcomes of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli septicemia at Srinagarind University Hospital, Thailand.
    Anunnatsiri S; Towiwat P; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2012 Sep; 43(5):1169-77. PubMed ID: 23431823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections.
    Yang YS; Ku CH; Lin JC; Shang ST; Chiu CH; Yeh KM; Lin CC; Chang FY
    J Microbiol Immunol Infect; 2010 Jun; 43(3):194-9. PubMed ID: 21291846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel.
    Laupland KB; Church DL; Vidakovich J; Mucenski M; Pitout JD
    J Infect; 2008 Dec; 57(6):441-8. PubMed ID: 18990451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for community-acquired infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Reiter KC; Fuchs SC; Barcellos NT; Zavascki AP
    Arch Intern Med; 2009 Apr; 169(8):811; author reply 811-2. PubMed ID: 19398696
    [No Abstract]   [Full Text] [Related]  

  • 27. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
    Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
    Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia.
    Martinez P; Garzón D; Mattar S
    Braz J Infect Dis; 2012; 16(5):420-5. PubMed ID: 22964287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
    J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
    Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
    J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for community- and health facility-acquired extended-spectrum β-lactamase-producing bacterial infections in patients at the University of Minnesota Medical Center, Fairview.
    Siedelman L; Kline S; Duval S
    Am J Infect Control; 2012 Nov; 40(9):849-53. PubMed ID: 22325481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
    Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Ipekci T; Seyman D; Berk H; Celik O
    J Infect Chemother; 2014 Dec; 20(12):762-7. PubMed ID: 25179392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)].
    Angel Díaz M; Ramón Hernández J; Martínez-Martínez L; Rodríguez-Baño J; Pascual A;
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):503-10. PubMed ID: 19329230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary tract infections owing to ESBL-producing bacteria: microorganisms change--clinical pattern does not.
    Özçakar ZB; Yalçınkaya F; Kavaz A; Kadıoğlu G; Elhan AH; Aysev D; Güriz H; Ekim M
    Acta Paediatr; 2011 Aug; 100(8):e61-4. PubMed ID: 21392102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
    Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
    Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
    Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
    J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal abscess due to Escherichia coli in a child.
    Baradkar VP; Mathur M; Kumar S
    Saudi J Kidney Dis Transpl; 2011 Nov; 22(6):1215-8. PubMed ID: 22089786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.